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Abstract
Background: Studies of the role of the cytokine macrophage-migration-inhibitory-factor (MIF) in
malignant tumors have revealed its stimulating influence on cell-cycle progression, angiogenesis and
anti-apoptosis.
Results: Here we show that in vitro targeting MIF in cultures of human malignant glioblastoma cells
by either antisense plasmid introduction or anti-MIF antibody treatment reduced the growth rates
of tumor cells. Of note is the marked decrease of proliferation under confluent and over-confluent
conditions, implying a role of MIF in overcoming contact inhibition. Several proteins involved in
contact inhibition including p27, p21, p53 and CEBPalpha are upregulated in the MIF antisense
clones indicating a restoration of contact inhibition in the tumor cells. Correspondingly, we
observed a marked increase in MIF mRNA and protein content under higher cell densities in LN18
cells. Furthermore, we showed the relevance of the enzymatic active site of MIF for the
proliferation of glioblastoma cells by using the MIF-tautomerase inhibitor ISO-1.
Conclusion: Our study adds another puzzle stone to the role of MIF in tumor growth and
progression by showing the importance of MIF for overcoming contact inhibition.
Background
The cytokine macrophage migration inhibitory factor
(MIF) has long been known as a modulator of the
immune response towards various infectious agents [1-4]
Over the last years, its role in other disease-related proc-
esses, in particular neoplastic disorders, has been eluci-
dated [5]. MIF is expressed in various malignant tumors,
comprising ectodermal [6], mesenchymal [7,8] and endo-
dermal cell types [9,10]. MIF functions in multiple ways
to boost tumor growth by promoting angiogenesis [11-
13], stimulating cell cycle progression [8,10,14], inhibit-
ing apoptosis [15,16] and preventing NK cell lysis [6]. MIF
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expression in tumor cell lines is regulated by growth fac-
tors [10] and cell stress [7,17]. Suppression of MIF func-
tion by anti-MIF antibody treatment and MIF-antisense
transfection alters the proliferate state of tumor cells in
vivo and in vitro [10,12,13]. Additionally, MIF has been
identified as a promoter of carcinogenesis in an intestinal
tumor model [18]. Recently, a MIF receptor complex con-
sisting of the invariant chain of the MHC complex CD74
and the hyaluronate receptor CD44 has been identified
[19]. The CD44 protein has also been implicated in medi-
ating contact inhibition in various cell types [20].
The expression of MIF has been described in tumours of
the central nervous system and the potential role for
tumour developement and progression in the brain has
been recently reviewed [21]. In particular a strong increase
of MIF expression in human glioblastoma multiforme has
been reported by several investigators [7,22,23]. Glioblas-
toma multiforme belongs to the most malignant tumors
known in men [24]. They infiltrate and displace normal
brain tissue and therefore must have invoked a potent
mechanism to overcome classical contact inhibition.
The aim of the study was to find out whether MIF plays a
role in these altered growth processes in gliomas and also
to test whether it might be a promising target for cancer
therapy. We therefore analyzed the growth of human gli-
oma cell lines in vitro while targeting the MIF function in
various ways. Special attention was drawn to proliferative
responses under confluent and over-confluent cell culture
conditions.
Methods
Cell Culture
Human glioma cell lines LN18 and LN229 were grown in
Dulbecco's modified eagle medium (DMEM) (Gibco-Life
Technologies, Eggenstein, Germany) supplemented with
5% fetal calf serum (FCS) (Seromed, Berlin, Germany),
1% penicillin/streptomycin (Serva, Heidelberg, Ger-
many) and 1% L-glutamine (Gibco-Life Technologies,
Eggenstein, Germany).
Plasmid cloning
The entire human MIF cDNA was cloned in antisense ori-
entation into the BamH1/EcoRV restriction sites of the
pcDNA 3.1/Myc-His vector (Gibco-Life Technologies,
Eggenstein, Germany).
Transfection
The LN18 cells were transfected at semiconfluent cell den-
sity with the linearized antisense and control plasmid
with the Lipofectamin reagent (Gibco-Life Technologies,
Eggenstein, Germany). Stable transfectants were selected
by adding 1 mg/ml G418 (Invitrogen, Leek, Netherlands)
to the cultures. After 4 weeks, the remaining cells were
plated out highly diluted and the emerging clones picked
with a sterilized needle and further propagated. From the
initially picked 24 antisense clones (Additional file 1),
two of these (termed as1 and as2) were chosen for the
experiments because of their high consistent MIF anti-
sense production. Seven empty vector transfected clones
were generated in a similar way and clone 5 (here after
termed c1) was used as a control for all experiments with
the antisenseMIF clones.
RNA preparation and Northern blot analysis
Total RNA was prepared by the TRIzol method (Gibco-
Life Technologies, Eggenstein, Germany). RNA samples (5
μg) were separated on 1% agarose gels. The RNA was blot-
ted with 20× SSC (1× SSC is 0.15 M NaCl plus 0.015 M
sodium citrate) onto a positively charged nylon mem-
brane (Boehringer GmbH, Mannheim, Germany). After
UV-cross-linking, hybridization was performed under
continuous rotation in a hybridization oven (Biometra,
Goettingen, Germany). The membranes were hybridized
with digoxigenin (DIG)-labeled antisense riboprobes
overnight under highly stringent conditions in 50% for-
mamide at 68°C and finally washed in 0.1% SSC, 0.1%
sodium dodecyl sulfate at the same temperature. Hybrid-
ized DIG-labeled riboprobes were visualized with the DIG
nucleic acid detection kit (Boehringer) and CPD-Star
chemiluminescence substrate (Tropix, Bedford, Mass.;
distributed by Serva, Heidelberg, Germany). Equal load-
ing of the RNA was confirmed by staining of 18S and 28S
RNA wth methylene blue. Quantification of band intensi-
ties were done with ImageJ (NIH, Bethesda, USA) and
normalized to 18S RNA. Results represent the mean of at
least 4 independent experiments.
Western blot
Protein samples were prepared by lyszing cells in 1% Tri-
ton containing proteinase and phosphatase inhibitors.
Supernatans were concentrated 20-fold with 10 kDa Cen-
tricon filter columns (Millipore, Billerica, USA) prior to
addition of sample buffer. Western blotting was per-
formed by the NuPAGE electrophoresis system (Novex,
San Diego, USA) using 4 to 12% N, N-methylenebisacry-
lamide-Tris gels. Proteins were transferred onto Optitran
BA-S83 membranes (Schleicher & Schuell, Dassel, Ger-
many). The antibodies used were polyclonal anti-human
MIF (1:4000) rabbit immunoglobulin G (IgG) as
described earlier [1], anti-p21 (1:1000), anti-p27
(1:1000), anti-C/EBPalpha (1:1000), anti-CD74 (1:500),
anti-Erk2 (1:1000), anti-phospho-Erk (1:2000), anti-pan-
Akt (1:1000), anti-beta-Actin (1:2000) (all from Santa
Cruz, La Jolla, USA), anti-p53 (1:1000), anti-phospho-Akt
(1:2000) (all from Cell Signaling, Danvers, USA), anti-
CD44 (1:500)(BD Bioscience Pharmingen, Bedford, USA)
and peroxidase-labeled goat anti-rabbit IgG and anti-
mouse IgG diluted 1/2000 in 5% milk in TBS/0,05%BMC Cancer 2009, 9:464 http://www.biomedcentral.com/1471-2407/9/464
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Tween (Cell Signalling, Danvers, USA). The bands were
visualized by an enhanced chemiluminescence detection
system, as recommended by the manufacturer (SuperSig-
nal ULTRA; Pierce, Rockford; USA). Quantification of
band intensities were done with ImageJ (NIH, Bethesda,
USA) and normalized to Actin if appropriate. Results rep-
resent the mean of at least 3 independent experiments.
BrdU assay
The cells were plated out in the stated numbers (see figure
legend) in 96-well plates (Costar Corporation, Cam-
bridge, USA) and incubated for 24 h prior to the experi-
ments. The cells were incubated for 6 h with fresh
medium supplemented with either anti MIF-antibodies or
the MIF-inhibitor ISO-1 and then for additional 2 h when
the BrdU labeling reagent was added. For experiments
with recombinant MIF cells were pre-treated with 10 and
50 ng/ml recombinant human MIF for 12 h before addi-
tion of BrdU labeling reagent for another 2 h. The assay
was performed using the Cell proliferation ELISA, BrdU
chemiluminescence (Boehringer, Mannheim, Germany)
according to the manufacturers instructions. The final
results were obtained by reading the chemiluminescence
values (relative light units (rlu) with a Lumistar auto-
mated plate reader (bmg, Offenburg, Germany). Results
are given as average of relative values of controls with SD
of eight simultaneous experiments. Statistics were calcu-
lated using Mann-Whitney unpaired non-parametric test
and a p-value < 0.05 was regarded significant. All experi-
ments have at least been repeated three times with similar
results.
Amido-black-Assay
Over a period of several days, growth was assessed by
staining the cells for intracellular protein content. The
protein staining was accomplished by using the amido-
black method [25]. In brief, the cells were plated out at
5000 cells/well on multiple 96-well plates and fed every
other day. For experiments with addition of MIF to culture
media, recombinant human MIF was added at 10 ng/ml
and 50 ng/ml with every medium change. Every day, the
cells in one plate were fixed and denatured with formalde-
hyde and stained with amido-black solution. After drying
of the plate, the amido-black dye was eluted from protein
bound with NaOH and the light absorption at 620 nm
was recorded with an automated plate reader. Results are
given as averages of relative values of controls with SD of
eight simultaneous experiments. Statistics were calculated
using Mann-Whitney unpaired non-parametric test and a
p-value < 0.05 was regarded significant. The experiments
have been repeated three times with similar results.
MIF blocking antibody
The antibodies against human MIF were initially raised in
rabbits, following a standard immunization protocol.
Monoclonal antibodies were then produced from the
fusion of myeloma cells and antibody-producing B-lym-
phocytes (Institute of Biotechnology Vilnius, Lithuania).
Binding of the monoclonal antibodies to MIF was con-
firmed by specific ELISA The antibody was purified from
ascites by sepharose columns using Kaptiv-M (Tecnogen,
Piana di Monte Verna, Italy).
Small compound MIF inhibitor
The synthetic MIF inhibitor, (S,R)-3-(4-Hydrophenyl)-
4,5-dihydro-5-isoazole acetic acid methyl ester (ISO-1)
has been recently shown to covalently bind to the D-
dopachrome tautomerase activity site of MIF and inhibits
several biological activities of MIF in vitro and in vivo
[26]. The inhibitor ISO-1 (provided by Y. Al-Abed) was
solubilized in DMSO at a concentration of 10 μg/μl
(equivalent to 42 mM) and further diluted in PBS if
required. For all experiments DMSO only treated cells
served as a control.
Recombinant human MIF
Human MIF cDNA was cloned into the pET-17b vector
(Novagen, Madison, USA) and expressed in Escherichia
coli BL-21 (DE3) strain after induction with 0.4 mM iso-
propyl -D-thiogalactopyranoside (IPTG) and purified
from the soluble fraction of the cell lysate by two-step
high-pressure liquid chromatography (HPLC): (i) size
exclusion HPLC on Bio-Sil TSK 250 (Bio-Rad, Munich,
Germany) and (ii) ion-exchange HPLC on Ultropac TSK
CM-3SW (LKB/Pharmacia, Freiburg, Germany). Biologi-
cal activity has been confirmed using proliferation assay
in human fibroblasts (unpublished data) and calcium
release assay [27].
FACS analysis
Cells were harvested by trypsinization and blocked in
human serum. Staining for CD44 and CD74 was per-
formed using the following antibodies: anti-human
CD44-PE (eBioscience, San Diego, USA), anti-human
CD74-FITC (BD Bioscience, Bedford, USA) and corre-
sponding isotype controls (eBioscience, San Diego, USA).
Analysis was carried out on a BD LSR II (BD, Bedford,
USA).
Results
The generation of stable MIF-antisense-transfected clones
is shown in Figure 1A. The MIF-antisense expression
resulted in a reduction of MIF protein level by 60% in
antisense clone as1 and 70% in the antisense clones as2
compared to wildtype (wt) cells (Figure 1B). It is of note
that the antisense clones displayed an upregulated MIF-
sense mRNA. In confluent cultures there is a marked dif-
ference in the morphologic appearance of wildtype and
antisense clones. While the wt and the control vector-
transfected cells (c1) display a more rounded and smallBMC Cancer 2009, 9:464 http://www.biomedcentral.com/1471-2407/9/464
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cell shape in dense areas, the antisense clones rest in an
ellipsoid and larger structure (Figure 1C). In semiconflu-
ent cultures, the cells show nearly similar morphology
(data not shown). This morphologic difference correlated
with an altered proliferation characteristic of the antisense
clones. In a time kinetic growth analysis over eight days
the antisense clones grew slower and reached only 48% (p
0.0043) and 57% (p 0.0007) respectively of the cell den-
sity of wildtype cells (Figure 2A). While having the same
DNA synthesis rate at low densities, the rate was reduced
in the as1 and as2 clones to 50% (p 0.0006) and 54% (p
0.0006), respectively at higher cell densities compared
with wt and control cells (Figure 2B). Addition of recom-
binant human MIF to the wt and as clones resulted in a
small increase in proliferation in the as clones in the short
term with only marginal effects in wt and control cells, but
did not lead to a sustained growth response in the long
term (Additional file 2).
According to these functional data, we could show the
increased expression of proteins associated with contact
MIF targeting by antisense transfection results in reduced MIF  protein and altered morphology of glioma cells Figure 1
MIF targeting by antisense transfection results in 
reduced MIF protein and altered morphology of gli-
oma cells. Human LN18 glioma cells transfected with an 
antisense-RNA MIF construct and corresponding antisense-
expressing clones (as1 + as2) were selected (A). These cells 
showed a markedly reduced MIF protein expression (B) and 
altered cell morphology in culture compared to wildtype 
(wt) and empty vector transfected control cells (c1) (C). MIF 
expression ratios have been calculated from MIF expression 
relative to 18S (A) or Actin (B) in three independent experi-
ments.
wt     as1  as2
MIF mRNA
MIF mRNA (antisense)
28 S
18 S
A
B
MIF
Actin
wt  as1  as2
C
c1
as1
as2
wt
1    0.4  0.3     MIF/Actin
1       1.3      1.2        MIF/18S
MIF targeting by antisense transfection results in reduced  proliferation and restoration of contact inhibition Figure 2
MIF targeting by antisense transfection results in 
reduced proliferation and restoration of contact inhi-
bition. The generated LN18 MIF antisense-expressing clones 
(as1 + as2) and controls (wildtype wt, control - empty vec-
tor-transfected - clone c1) were plated on 96-well plates at 
the same cell number. Growth was measured the following 
days by amido-black assay. At day 8 the antisense clones as1 
and as2 reached 48% (p 0.0043) and 57% (p 0.0007), respec-
tively of the cell density of wildtype cells (A). DNA synthesis 
was significantly (* p < 0.005) compromised in clones at 
higher cell densities (B).
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inhibition in the antisense-transfected LN18 cells at low
plating density. The antisense clones showed an upregu-
lated expression of p21, p27, p53 and CEBP/alpha at
semi-confluent culture conditions compared to wt cells,
(Figure 3A). When cells were plated at overconfluent cell
density the wt and control cells also upregulated the
above mentioned proteins, but there was still a higher
expression of the cell cycle inhibitor p27 in the antisense
clones. Since an influence of MIF on mitogenic signalling
has been reported previously [11,28], we examined the
activation of Akt and Erk in the antisense clones. We
found a strong reduction of phospho-Erk and a modest
reduction of phospho-Akt in the antisense clones com-
pared to wildtype and control cells (Figure 3C).
To further analyse the link between MIF and growth regu-
lation we examined the expression of MIF at different cell
densities. In addition to the LN18 cells we also studied
another glioma cell line LN229. The LN229 cells were
chosen because of morphological signs of contact inhibi-
tion at high cell densities which correlated with a reduced
DNA synthesis rate at confluency (Additional file 3). In
contrast, the LN18 cell cultures displayed overgrowth at
higher cell densities and continued DNA synthesis at con-
fluency. Analysis of the MIF mRNA expression under dif-
ferent cell densities of wildtype glioma cells, LN18 and
LN229, revealed a marked difference between these cells.
LN18 cells showed high MIF mRNA levels at all cell den-
sities, while LN229 cells had reduced levels under conflu-
ent culture conditions (Figure 4A). Despite these
differences in mRNA levels the intracellular MIF levels in
both cell lines were increased at higher cell densities to a
similar extend (3.7-fold and 4.9-fold for LN18 and LN229
cells, respectively) (Figure 4B). The extracellular MIF levels
remained constant (LN229) or increased up tp 3-fold
(LN18) (Figure 4C).
When targeting the extracellular MIF protein by addition
of monoclonal anti-MIF antibodies to the cell culture
medium, there was only a modest growth reduction of
LN18 cells under confluent culture conditions (30% of
untreated cells, p 0.0286) with semiconfluent densities
being non affected (Figure 5A). In contrast, LN229 cells
showed a reduced growth rate at all cell densities, but still
the maximal suppression (44%, p 0.0286) was seen under
confluent culture conditions (Figure 5B). The use of the
chemical inhibitor of the catalytic MIF activity, ISO-1,
confirmed the results obtained with the antibody experi-
ments. Similarly, the maximal growth reduction was elic-
ited under the highest cell density (Figure 6A and 6B)
without affecting cell viability (data not shown). In the
LN229 cells the maximal response was 56% reduction (p
0.0002) whereas in the LN18 cells the BrdU uptake could
be suppressed even more (78%, p < 0.0001) compared to
DMSO treated controls. The addition of ISO-1 to the cell
cultures resulted in a decrease of the basal activity of the
mitogenic signalling by Akt and Erk1/2 as shown by phos-
pho-specific Western Blotting in both cell lines (Figure
6C).
To confirm the presence of the MIF receptor proteins in
the cells we performed FACS analysis and Western Blott-
ting for CD44 and CD74. We detected a high expression
of CD44 in both cell lines (Figure 7A) by FACS analysis,
which was confirmed by Western Blotting (Figure 7B).
Interestingly, at low density only high molecular weight
isoform of CD44 could be detected, which represent the
isofrom CD44v9. At higher cell density there is also
expression of the normal 89 kDa isoform. Analysis of
CD74 expression by flow cytometry gave only a weak sig-
nal, which was not higher than the corresponding isotype
control (Figure 7A). But CD74 expression could be veri-
fied by Western blotting (Figure 7C). It is of note, that the
protein levels were much higher in the LN229 cells and
showed an upregulation by cell density in these cells. We
did not find a regulation of either CD44 or CD74 upon
MIF inhibition by the MIF inhibitor ISO-1 (Additional file
4).
Discussion
In line with other studies on the role of MIF in tumor biol-
ogy, our data show a profound influence of MIF targeting
on the proliferative response in human glioma cells.
Given the high grade of malignancy of glioblastomas [12],
which normally implies many redundant growth promot-
ing pathways, it seems puzzling that targeting a single pro-
tein gives responses with up to 60% growth reduction.
This could indicate a pivotal role for MIF as a "second
messenger" for other growth stimuli like EGF in an auto-
crine fashion. According to earlier studies there is a
marked upregulation of MIF mRNA and protein after
stimulation of colon derived cells with various growth fac-
tors [10]. This idea is also supported by the study of
Mitchell and colleagues who found a sustained MAPK
activity upon stimulation with MIF rather than a transient
upregulation [28]. It is conceivable that MIF is a common
permissive factor for other growth stimuli rather than pos-
sessing a direct stimulating activity. This model renders
the MIF protein an interesting and promising target for
further research in cancer therapy, because one could tar-
get a "common pathway" and not one of plenty alterna-
tives.
One of the key events in tumor formation is the loss of
contact inhibition resulting in an unrestricted growth of
the cells despite overgrowth [29,30]. It has been shown
previously that fibroblasts from MIF knockout mice reach
lower cell densities than their wildtype counterparts [8].
Here we report for the first time a link between MIF and
overriding contact inhibition in tumor cell lines. TheBMC Cancer 2009, 9:464 http://www.biomedcentral.com/1471-2407/9/464
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MIF targeting results in upregulation of contact inhibition markers and reduced mitogenic signaling Figure 3
MIF targeting results in upregulation of contact inhibition markers and reduced mitogenic signaling. The anti-
sense clones showed a restoration of contact inhibition indicated by increased expression of classical contact inhibition mark-
ers (p21, p27, p53 and C/EBPα) at lower cell densities (A). Densiometric quantification of the contact inhibitions markers 
relative to Actin of three independent experiments is shown in (B). Analysis of mitogenic signaling pathways revealed a marked 
reduction in basal Erk1/2 activity and a less pronounced reduction in Akt activity (C).
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Glioma cells exhibit an increasing MIF expression under higher cell densities Figure 4
Glioma cells exhibit an increasing MIF expression under higher cell densities. The glioma cell lines LN18 and LN229 
were plated at increasing cell densities. They display a much higher MIF protein content at high cell densities (B). The MIF 
mRNA expression was not affected by cell density in the LN18 cells, but was reduced in LN229 cells (A). Extracellular MIF lev-
els remained constant (LN229) or increased (LN18) with cell density (C). MIF mRNA expression ratios relative to 18S RNA 
and MIF protein expression ratios relative to Actin were calculated from four independent experiments.BMC Cancer 2009, 9:464 http://www.biomedcentral.com/1471-2407/9/464
Page 8 of 13
(page number not for citation purposes)
expression of several proteins which mediate contact inhi-
bition are modulated by MIF. Of note, the MIF antisense
expressing cells show a much higher expression of classic
cell cycle inhibitors like p21 and p27. In addition we
found a reduction in basal state activity of the two
mitogenic signalling pathways Erk and Akt, which might
acount for the changes seen in cell cycle regulator expres-
sion. Similar obeservation have been made using siRNA
targeting of MIF in prostate cancer [31] and ovarian cancer
cells [32]. Furthermore, the antisense clones show a
higher expression of the MIF sense mRNA, which might
represent a mechanism to counterregulate the reduced
MIF protein levels pointing to a tight feedback regulation
of protein levels.
To our surprise, we were unable to rescue the phenotype
of the as clones by adding recombinant human MIF to the
cell cultures. Although the addition of recMIF to the as
clones increased their proliferation in the short term, it
did not fully restore normal growth nor growth kinetics in
the longterm. Thus one might speculate, whether the
effect of MIF in the LN18 cells is not only mediated by
extracellular protein, but also by intracellular levels of
MIF. Indeed, MIF has not only cell surface binding part-
ners (e.g. CD74), but also intracellular binding partners
(e.g. Jab1 and p53) which have well established roles in
cell cycle regulation. Support for this hypothesis can be
drawn from the fact, that the MIF inhibitor ISO-1 (which
blocks extra- and intracellular MIF activity [33]) has a
stronger effect on proliferation than MIF antibody treat-
ment (blocks only extracellular MIF) in LN18 cells. In
addition the LN18 cells show only a weak expression lev-
els of the MIF receptor CD74, which has been correlated
with the responsiveness of prostate cells to exogenous MIF
[31]. A recent publication even reported a lack of CD74
expression in LN18 cells by PCR, confirming our findings
[34]. Although the low CD74 expression in the LN18 cells
most likely account for the unresponsiveness to exogene-
ous MIF, a different glioma cell line not expressing CD74
has been found to still be responsive to recombinant MIF
- arguing for an alternative MIF receptor [34]. Another
explanation for the reduced responsiveness of the as
clones to exogeneous MIF might be possible post-transla-
tional modifications of endogenous MIF in opposition to
recombinant MIF raised in E. coli, which might be impor-
tant for the interaction with CD74 or alternative MIF
receptors and for uptake of MIF into the cells.
Recently, the signal transduction of MIF has been linked
to binding to CD74 and CD44. We could confirm the
expression of both membrane proteins in our cell lines
and found an increase in the expression with higher cell
densities for in the LN229 cells. Interestingly, CD44 plays
a key role in mediating contact inhibition on binding of
hyaluronic acid [20]. Given the demonstrated binding of
MIF to the CD74 and CD44 complex, an interference with
the perception of contact inhibition signals by CD44
seems intriguing. Further research is needed to elucidate
the exact mechanism involving the action of MIF under
these circumstances.
It has long been debated whether the enzymatic tautoi-
somerase activity might be important for the biological
function of MIF. Adding the specific MIF-tautomerase
inhibitor ISO-1 to our cell cultures confirmed our results
obtained with the antisense clones and antibody treat-
ment. According to a recent study the enzymatic activity of
MIF itself does not influence the biological functionality,
but the conformation of the enzymatic domain is critical
for the function of MIF [35]. The possible inhibitory activ-
ity of ISO-1 on MIF-promoted tumor suppression has
recently been described in two in vivo models [31]. Here,
we were able to extend these findings to a different
Blocking MIF with a monoclonal antibody decreases prolifer- ation of glioblastoma cell lines at high cell density Figure 5
Blocking MIF with a monoclonal antibody decreases 
proliferation of glioblastoma cell lines at high cell 
density. The human glioblastoma cell lines LN18 (A) and 
LN229 (B) were incubated with a monoclonal MIF antibody 
(6F12) for 6 h. Measurement of DNA synthesis at low and 
high cell densities revealed a significant reduction of prolifer-
ation at high density (* p < 0.05, n.s. not significant).
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Inhibiting MIFs intrinsic tautomerase activity by the small compound inhibitor ISO-1 reduced proliferation and mitogenic signal- ling in glioblastoma cells Figure 6
Inhibiting MIFs intrinsic tautomerase activity by the small compound inhibitor ISO-1 reduced proliferation and 
mitogenic signalling in glioblastoma cells. Small compound inhibitors can block the tautomerase activity of MIF. Incubat-
ing LN229 (A) and LN18 (B) cells with increasing concentrations of the inhibitor ISO-1 for 6 h (LN229) or 24 h (LN18) 
reduced cell proliferation. (* p < 0.05, *** p < 0.0005). Western Blot analysis of Akt and Erk1/2 phosphorylation showed a 
marked reduction in basal activity after ISO-1 treatment for 6 h in both cell lines (C). Akt and Erk phosphorylation ratios were 
calculated from two independent experiments.
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LN18 and LN229 cells express the MIF receptor complex proteins CD44 and CD74 Figure 7
LN18 and LN229 cells express the MIF receptor complex proteins CD44 and CD74. FACS analysis revealed a 
strong expression of CD44 on both cell lines (A), which was confirmed by Western Blotting (B). Analysis of CD74 expression 
by FACS did not show a significant difference by flow cytometry (A), but strong expression of CD74 in the LN229 and weak 
expression in the LN18 cells could be detected by Western Blotting (C). Expression ratios for CD44 andCD74 relative to 
Actin have been calculated from three independent experiments. For FACS analysis filled area show autofluorescence of 
unstained cells and the thin graph represents the staining of the isotype control, whereas the signal of the PE labeled anti CD44 
and FITC labeled anti CD74 is shown by the bold graph.
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tumour entity. In addition, we could show for the first
time an effect of MIF inhibition by ISO-1 on mitogenic
signalling by the MAPK/Erk and PI3K/Akt pathway. These
data are in line with previous published reports targeting
MIF by specific MIF neutralizing antibodies [11,28].
The regulation of the MIF expression by cell density gives
more support to our hypothesis that MIF mediates the
overcoming of contact inhibition. There was an increasee
in MIF protein levels in both cell lines, despite constant
(LN18) or even decreasing (LN229) mRNA levels with
higher cell density. Since the extracellular MIF levels
remain constant or are only disproportionately increased
with increasing cell numbers (3-fold MIF upregulation,
but 20-fold more cells), the increased MIF levels could be
due to an accumulation of nonsecreted protein. A regula-
tion of MIF protein levels by a post-translational mecha-
nism affecting protein stability might be another
mechanism accounting for the increase of intracellular
MIF protein with cell densitiy despite similar or decreas-
ing mRNA levels [36]. Another aspect of this finding is the
MIF accumulation under cell stress, which also has been
shown for various other agents and conditions inducing
cell stress. Thus, the elevated MIF levels might help to pro-
tect the cells from induced cell death under stress by anti-
apoptotic effects mediated by p53 [7,16]. Targeting MIF
under these circumstances might alter the tumors' capa-
bility of withstanding radiation or chemotherapy, thereby
increasing effectiveness and limiting side effects. Indeed
targeting MIF by neutralizing antibody has recently been
shown to enhance chemotherapy efficacy in breast cancer
cells [37].
Our preliminary results from in vitro studies need to be
followed by well-designed animal studies to further eval-
uate MIF function in cancer progression and in response
to standard treatment. Our MIF antisense clones could be
valuable tools for this purpose. In addition, the MIF-
inhibitor ISO-1 used in this study could be a promising
anticancer agent for further research.
Conclusions
Our study provides new insight into the role of MIF in
tumor growth and progression by showing the impor-
tance of MIF for overcoming contact inhibition.
We showed that in vitro targeting MIF in cultures of
human malignant glioblastoma cells by either antisense
plasmid introduction or anti-MIF antibody treatment
reduced the growth rates of tumor cells. Of note was the
marked decrease of proliferation under confluent and
over-confluent conditions, implying a role of MIF in over-
coming contact inhibition. Several proteins involved in
contact inhibition including p27, p21, p53 and CEBPal-
pha were upregulated in the MIF antisense clones indicat-
ing a restoration of contact inhibition in the tumor cells.
Furthermore, we showed the relevance of the enzymatic
active site of MIF for the proliferation of glioblastoma
cells by using the MIF-tautomerase inhibitor ISO-1
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